Morgans names more of the best ASX 200 shares to buy in December

These ASX 200 shares have been given the thumbs up by analysts at Morgans in December.

| More on:
Man sits smiling at a computer showing graphs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The team at Morgans has been busy picking out its best ASX 200 share ideas for December.

The first two ASX 200 shares we looked at can be found here. Read on for two more picks:

Aristocrat Leisure Limited (ASX: ALL)

Morgans has Aristocrat Leisure on its list again this month. It is a gaming technology company with a portfolio of world-class poker machines and digital games, as well as a fledgling real money gaming offering.

The broker believes the ASX 200 share is well-placed to grow strongly organically over the long term. It also notes that it has the balance sheet strength to supercharge its growth with acquisitions. Morgans said:

We have three key reasons for being positive on ALL. They are: (1) long-term organic growth potential. ALL is better capitalised than many of its competitors and has what we regard as a strong platform to continue investment in design and development in both its land-based gaming and digital businesses; (2) strong cash conversion and ROCE. ALL is a capital-light business despite its ongoing investment in Gaming Operations capex and working capital. It has a high level of cash conversion and ROCE; and (3) strong platform for investment. ALL has funding capacity for organic and inorganic investment in online RMG, even after the recent buyback. Its current available liquidity is $3.8bn.

Morgans has an add rating and a $46 price target on its shares.

ResMed Inc (ASX: RMD)

Another ASX 200 share that Morgans rates highly is sleep disorder treatment company ResMed.

Its analysts appear to believe the recent selloff due to Ozempic concerns has created a buying opportunity for investors. It explains:

While weight loss drugs have grabbed headlines and investor attention, we see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers. Although quarters are likely to remain volatile, nothing changes our view that the company remains well placed and uniquely positioned as it builds a patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.

The broker has an add rating and a $32.74 price target on ResMed's shares.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a miner wearing a hard hat smiles as he stands in front of heavy earth moving equipment on a barren mine site.
Materials Shares

Should you buy BHP shares following the miner's half-year results?

Should you be snapping up this mining giant's shares? Here's what this broker thinks.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Broker Notes

The best ASX shares to buy with $1,000 right now

Analysts at Morgans see these shares as top options this month.

Read more »

gambling asx share price fall represented by woman in soccer had looking frustrated at tablet screen
Share Fallers

This ASX stock has halved in 6 months. It could be a bargain buy

Remember, what the share price did in the past has nothing to do with what it could do in the…

Read more »

Happy couple with a car dealer.
Broker Notes

Goldman Sachs says buy despite this ASX 200 stock trading at a record high

Let's find out why.

Read more »

A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
Broker Notes

How these 4 ASX 200 shares just gained major broker upgrades

Brokers are forecasting substantial 2024 share price gains from these four ASX 200 shares.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Materials Shares

Liontown shares crash 8% on broker downgrade

This lithium stock has been the victim of a broker downgrade today.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Bank Shares

Are Westpac shares a buy following the bank's results?

Is now a good time to snap up this banking giant's shares?

Read more »

Two miners standing together.
Resources Shares

2 battered ASX mining shares to buy for cheap right now

The global economy is set to improve in the coming year. That's why one expert is seeing a huge 58%…

Read more »